Ichita Hasegawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ichita Hasegawa has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Motoko Y. Kimura
Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan
34 shared publications - Ryo Koyama-Nasu
Department of Experimental Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan
34 shared publications - Yangsong Wang
Department of Experimental Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan
34 shared publications - Yukihiro Endo
Department of Experimental Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan
34 shared publications - Atsushi Onodera
Institute for Advanced Academic Research, Chiba University, Chiba, Japan
33 shared publications - Kiyoshi Hirahara
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan
33 shared publications
Latest Publications
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (30) , eadx9864
Distinct thymic pDC populations promote tumor immune tolerance through complementary mechanisms
Thymic central tolerance is crucial for preventing autoimmunity, but its contribution to tumor immune evasion remains poorly understood. Here, we demonstrate that plasmacytoid dendritic cells (pDCs) in the thymus have two distinct subsets, accumulating in the thymus of tumor-bearing mice, contributing to immune tolerance through clonal deletion of tumor-specific T cells and reducing newly generated T cells. Mechanistically, common dendritic cell progenitor-derived pDCs (CDP-pDCs) capture tumor antigens and migrate to the thymus in a CCR9-dependent manner, where they present these antigens to induce clonal deletion of tumor-specific T cells. Concurrently, tumor progression inhibits T cell generation by promoting the accumulation of common lymphoid progenitor–derived pDCs (CLP-pDCs) within the thymus, which further produce type I interferon to alter thymic function. CCR9 deficiency prevents thymic accumulation of both pDCs, enhancing antitumor immunity and reducing tumor growth. Our findings reveal a previously unrecognized mechanism by which tumors hijack the physiological system to establish central tolerance against peripheral antigens, thereby promoting tolerance against themselves.
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (30) , eadx9864
Distinct thymic pDC populations promote tumor immune tolerance through complementary mechanisms
Thymic central tolerance is crucial for preventing autoimmunity, but its contribution to tumor immune evasion remains poorly understood. Here, we demonstrate that plasmacytoid dendritic cells (pDCs) in the thymus have two distinct subsets, accumulating in the thymus of tumor-bearing mice, contributing to immune tolerance through clonal deletion of tumor-specific T cells and reducing newly generated T cells. Mechanistically, common dendritic cell progenitor-derived pDCs (CDP-pDCs) capture tumor antigens and migrate to the thymus in a CCR9-dependent manner, where they present these antigens to induce clonal deletion of tumor-specific T cells. Concurrently, tumor progression inhibits T cell generation by promoting the accumulation of common lymphoid progenitor–derived pDCs (CLP-pDCs) within the thymus, which further produce type I interferon to alter thymic function. CCR9 deficiency prevents thymic accumulation of both pDCs, enhancing antitumor immunity and reducing tumor growth. Our findings reveal a previously unrecognized mechanism by which tumors hijack the physiological system to establish central tolerance against peripheral antigens, thereby promoting tolerance against themselves.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S2 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S1 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S1 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S3 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Table S3 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11 from CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11